In the context of cancer, increased survival of tumor-specific cytotoxic T cells can be achieved by interrupting the PD-1L/PD-1 or enhancing the 4-1BB signaling using specific antibodies, thereby increasing the anti-tumor effect [410]. This evidence concerns the gene TNFRSF9 and neoplasm.